Hong Kong Stock Movement
CF PHARMTECH rose by 17.47%. Based on recent key news:
<ol>
<li>
On March 16, the new drug clinical trial application for the inhalation powder candidate drug ICF001, independently developed by CF PHARMTECH, has been accepted by the National Medical Products Administration. This news has driven the stock price up, showing a positive market response to this innovative drug. Source: Economic Information Daily
</li>
<li>
On March 16, there was significant capital inflow in the Hong Kong stock market, with southbound funds accumulating a net inflow of over 180 billion RMB this year, becoming an important support for the capital market of Hong Kong stocks. This capital inflow trend provides a solid market foundation for individual stocks like CF PHARMTECH. Source: Yicai Global
</li>
<li>
On March 16, the profitability characteristics of the innovative drug industry were emphasized, with some leading companies already achieving profitability, and more companies are expected to enter the profit period in the future. This industry trend has enhanced market confidence in CF PHARMTECH. Source: Yicai Global
</li>
</ol>
Stocks with High Trading Volume in the Industry
CSPC Pharmaceutical Group rose by 1.65%. Based on recent key news:
<ol>
<li>
On March 17, the gene editing research results of CSPC Pharmaceutical Group were published in the journal Science Advances, enhancing market confidence in its R&amp;D capabilities and driving the stock price up. Source: People's Financial News
</li>
<li>
On March 16, CSPC Pharmaceutical Group's SYH2059 inhalation powder received clinical trial approval in China and the United States, showing progress in its innovative drug development and boosting investor confidence. Source: Zhitong Finance
</li>
<li>
On March 16, CSPC Innovative Pharmaceutical announced its performance for the year 2025. Despite revenue growth, net losses widened, raising market concerns about its profitability and affecting stock price volatility. Source: Zhitong Finance
</li>
</ol>
China Biologic Products Holdings rose by 1.32%. Based on recent news:
<ol>
<li>
On March 17, China Biologic Products announced that its subsidiary Beijing Tide Pharmaceutical's national Class 1 innovative drug TRD221 has received clinical trial approval from the National Medical Products Administration, intended for the treatment of osteoarthritis. This drug has shown dual effects of alleviating pain symptoms and improving structural damage in various mechanism-induced osteoarthritis animal models, with good safety, and has the potential to become a new treatment option for osteoarthritis. This news has boosted market confidence and driven the stock price up.
</li>
<li>
On March 17, Zhitong Finance reported that TRD221 is a globally innovative complex polysaccharide drug jointly developed by Beijing Tide and the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences. Polysaccharides have good biocompatibility and safety, but due to their complex mechanisms of action, there are many challenges in pharmaceutical research, quality control, and pharmacological evaluation, which have long restricted the R&amp;D progress of polysaccharide-based innovative drugs. This clinical approval will further enrich the group's innovative pipeline in the surgical/analgesic field, expected to fill existing treatment gaps and provide new treatment options for a large number of osteoarthritis patients
On March 18, the Economic Information Daily reported that TRD221 demonstrated dual effects of alleviating pain symptoms and improving structural damage in various mechanism-induced osteoarthritis animal models, with good safety, showing potential to become a new treatment option for osteoarthritis. The approval of clinical trials for this drug further enhances market confidence in China's biopharmaceutical innovation capabilities. The demand for osteoarthritis treatment is high, and innovative drugs have significant potential.
</li>
</ol>
Hansoh Pharmaceutical rose by 0.79%. Based on recent news,
<ol>
<li>
On March 16, the profitability characteristics of the innovative drug industry were emphasized, with some leading companies already achieving profitability, and more companies expected to enter the profit period in the next two years, boosting market confidence and driving stock prices up.
</li>
<li>
On March 16, southbound funds continued to flow into Hong Kong stocks, with a cumulative net inflow exceeding RMB 180 billion this year, becoming an important support for Hong Kong stock funds and boosting Hansoh Pharmaceutical's stock price.
</li>
<li>
On March 16, despite the overall high volatility of Hong Kong stocks, structural opportunities emerged in individual stocks and sectors supported by southbound and overseas funds, benefiting Hansoh Pharmaceutical. The funding support for Hong Kong stocks is strong, with increased volatility.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Hengrui Medicine rose by 0.61%. Based on recent news,
<ol>
<li>
On March 16, Hengrui Medicine announced that its self-developed innovative drug, Hecolin, received approval for a new indication for the treatment of patients with severe aplastic anemia. This news boosted market confidence and drove stock prices up.
</li>
<li>
On March 16, a subsidiary of Hengrui Medicine received a clinical trial approval notice from the National Medical Products Administration for SHR-1819 injection and SHR-1905 injection, with smooth progress in the clinical trials of these new drugs, further enhancing investors' confidence in the company's R&amp;D capabilities.
</li>
<li>
On March 16, a subsidiary of Hengrui Medicine received acceptance of the drug listing application for fumaric acid lacosamide capsules from the National Medical Products Administration, which are used for the treatment of patients with paroxysmal nocturnal hemoglobinuria, demonstrating the company's innovation capabilities in the field of hematological disease treatment. The pharmaceutical industry has recently performed strongly, with significant R&amp;D progress
</li>
</ol>

02652

CF PHARMTECH rose 17.47%; CSPC Pharmaceutical Group rose 1.65%, with a transaction volume of HKD 59.53 million; China Biologic Products Holdings rose 1.32%, with a transaction volume of HKD 32.41 million; Hansoh Pharmaceutical rose 0.79%, with a transaction volume of HKD 30.24 million; Heng Rui Medicine rose 0.61%, with a market value of HKD 437.4 billion

Hong Kong stock movement: CF PHARMTECH rises 17.47%, driven by dual benefits of new drug approval and capital inflow boosting stock price surge